Transfusion Diagnostics Market By Product Type (Instruments; Reagents & Kits; Software & Services); By Technology (PCR-based Assays; Microarrays; Immunohematology; Next-generation Sequencing (NGS); Other Technologies); By Application (Blood Grouping; Disease Screening; Molecular Typing; Serological Testing); By End-User (Hospitals & Blood Banks; Diagnostic Laboratories; Research & Academic Institutes); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Transfusion Diagnostics Market Size & Overview

The Transfusion Diagnostics Market was valued at approximately $4.5 billion in 2024 and is projected to reach $7.1 billion by 2030, growing at a CAGR of 7.5% during the forecast period. This market plays a critical role in ensuring safe and effective blood transfusion practices by detecting blood group compatibility and screening for transfusion-transmissible infections (TTIs).

 

The increasing incidence of blood disorders, rising demand for blood transfusions due to trauma cases and surgical procedures, and advancements in molecular diagnostics are key drivers of market growth. Technological innovations such as automation, artificial intelligence (AI)-driven screening & next-generation sequencing (NGS) are enhancing the accuracy and efficiency of transfusion diagnostics. Additionally, strong regulatory frameworks, increasing blood donation rates & government initiatives promoting blood safety are further fueling market expansion. While North America currently holds the largest market share due to its advanced healthcare infrastructure, Asia-Pacific is expected to witness significant growth owing to rising healthcare investments & the growing need for blood safety measures.

 

Transfusion Diagnostics Market Dynamics:

Market Drivers:

Rising Prevalence of Blood Disorders

The rising incidence of blood-related disorders necessitates frequent blood transfusions, thereby boosting the demand for transfusion diagnostics. Millions of people in the US carry genes that can cause blood disorders like sickle cell disease & hemophilia. Sickle cell disease affects about 100,000 people in the United States. An estimated 1,698,339 people in the United States are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). The WHO estimates that hemoglobin disorders affect approximately 5% of the global population, with over 300,000 infants born annually with severe hemoglobin disorders. This high prevalence underscores the critical need for accurate blood transfusion diagnostics to ensure safe & compatible transfusions.

Growing Number of Surgical Procedures

The increase in surgical interventions contributes to the demand for blood transfusions & consequently, transfusion diagnostics. Data indicates that globally, there are approximately 310 Mn major surgeries performed each year, with a significant proportion requiring blood transfusion support. The number of hospitals performing thrombectomy has surged over the past five years. In 2015, around 100 hospitals conducted mechanical stroke thrombectomy procedures. By 2020, this number had escalated to over 900. According to Joint Commission regulations, hospitals must be designated as either a Comprehensive Stroke Center or a Thrombectomy-Capable Stroke Center to perform mechanical stroke thrombectomy. This substantial number of surgical procedures highlights the essential role of transfusion diagnostics in perioperative care.

 

Market Opportunities:

Technological Advancements in Diagnostic Tools

The development of advanced diagnostic technologies presents significant growth opportunities in the transfusion diagnostics market. Innovations such as nucleic acid amplification testing (NAT) & next-generation sequencing (NGS) have enhanced the accuracy & speed of blood screening processes. The U.S. Food & Drug Administration (FDA) has granted de novo clearance to an AI system developed by Scopio Labs for diagnosing blood disorders & cancer. This system leverages high-resolution microscopic imaging to analyze bone marrow biopsies. By enabling hemopathologists to remotely analyze bone marrow smears, the technology enhances efficiency & facilitates more accessible second opinions. The adoption of these technologies is expected to improve transfusion safety & expand market reach.

Expansion in Emerging Markets

Emerging economies offer a lucrative opportunity for market expansion due to improving healthcare infrastructure & increasing awareness of blood safety. Countries in the APAC region are experiencing a rise in healthcare investments, leading to the establishment of more blood banks & transfusion centers. This regional growth is anticipated to drive the demand for transfusion diagnostics.

 

Market Restraints:

High Costs of Advanced Diagnostic Instruments

The substantial investment required for advanced diagnostic equipment can be a barrier, particularly for healthcare facilities in resource-limited settings. The high costs associated with these instruments may limit their adoption, thereby restraining market growth.

Risk of Transfusion-Transmitted Infections (TTIs)

Despite rigorous screening, the potential for transfusion-transmitted infections remains a concern. The emergence of new pathogens & the window period of certain infections pose challenges to ensuring completely safe transfusions. This risk necessitates continuous advancements in diagnostic methods & can influence public perception, potentially impacting market dynamics.

 

Transfusion Diagnostics Market Segmentation: A Comprehensive Overview

By Product Type

• Instruments

• Reagents & Kits

• Software & Services

 

By Technology

• PCR-based Assays

• Microarrays

• Immunohematology

• Next-generation Sequencing (NGS)

• Other Technologies

 

By Application

• Blood Grouping

• Disease Screening

• Molecular Typing

• Serological Testing

 

By End-User

• Hospitals & Blood Banks

• Diagnostic Laboratories

• Research & Academic Institutes

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Transfusion Diagnostics Market Segment Analysis: Growth Trends Across Categories

By Product Type:

Leading Segment: Reagents & Kits

Reagents & kits hold the largest share of the transfusion diagnostics market. This segment accounts for nearly 45% of the total market share. The primary driver of growth is the increasing demand for reagents used in blood screening, disease detection, and blood typing. Reagents are essential for ensuring accurate diagnostics and are crucial in preventing the transmission of infectious diseases via blood transfusions.

Fastest-Growing Segment: Software & Services

The fastest-growing segment in transfusion diagnostics is Software & Services, with a CAGR of 8.5%. This growth is driven by the rising integration of digital technologies & automated systems in blood testing. Software solutions enhance data management, improve diagnostic efficiency & ensure compliance with stringent regulatory standards. The increasing adoption of laboratory management systems & diagnostic software, especially in large hospitals & diagnostic centers, is fueling this growth.

 

By Technology:

Leading Segment: PCR-based Assays

PCR-based assays are the leading technology in the transfusion diagnostics market, making up 40% of the market share. PCR technology is essential for detecting blood-borne pathogens like HIV, Hepatitis B & Hepatitis C in donor blood. This method provides high sensitivity, accuracy & speed, making it indispensable in blood testing, ensuring the safety of blood transfusions globally.

Fastest-Growing Segment: Next-generation Sequencing (NGS)

The fastest-growing technology segment is Next-generation Sequencing (NGS), with a CAGR of 10.2%. NGS offers advanced capabilities for genetic testing & the detection of rare pathogens or genetic markers that PCR may not identify. The increasing use of NGS in personalized medicine & the growth in molecular typing are contributing factors to this segment’s rapid expansion.

 

By Application:

Leading Segment: Blood Grouping

Blood grouping is the leading application in transfusion diagnostics, representing approximately 30% of the market share. Blood grouping is essential in preventing transfusion reactions, which has made it a vital component of transfusion diagnostics. Technological advancements in blood typing have made it more accurate & faster, supporting the growth of this segment.

Fastest-Growing Segment: Molecular Typing

Molecular typing is the fastest-growing application segment, with a CAGR of 9.1%. The rise in demand for molecular typing is largely attributed to its ability to identify genetic variations in blood types & pathogens. This is increasingly used in organ transplantation, research & for ensuring blood transfusion compatibility, particularly in regions with high ethnic diversity.

 

By End-User:

Leading Segment: Hospitals & Blood Banks

Hospitals and blood banks are the leading end-user segment, accounting for over 50% of the transfusion diagnostics market share. This dominance is driven by the critical role hospitals & blood banks play in providing safe blood supplies. Increased blood donations & the heightened demand for blood in surgeries & treatments have bolstered the growth of this segment.

Fastest-Growing Segment: Diagnostic Laboratories

Diagnostic laboratories are the fastest-growing end-user segment with a CAGR of 7.8%. The expansion of diagnostic laboratories is a result of the increasing need for precise & timely diagnostic services. Laboratories, particularly those focused on molecular diagnostics, are seeing growing demand as they support hospitals, research institutions & blood banks in the screening & identification of blood-borne diseases and pathogens.

 

By Region:

Leading Region: North America

North America holds the largest share of the transfusion diagnostics market, accounting for approximately 40% of the total market share. The strong presence of advanced healthcare infrastructure, along with an established regulatory framework, positions North America as the leading region. The demand for transfusion diagnostics is fueled by the high incidence of blood-related disorders & the extensive use of advanced technologies in this region.

Fastest-Growing Region: Asia-Pacific

APAC is the fastest-growing region in the transfusion diagnostics market, with a CAGR of 9.5%. The region’s growth is driven by increasing healthcare expenditures, rising awareness of blood safety & the expansion of healthcare infrastructure. Countries like China & India are seeing significant investments in their healthcare sectors & the rising prevalence of blood-borne diseases is increasing the need for reliable & efficient blood testing technologies. Additionally, the rising number of blood donations and the government’s efforts to improve healthcare access contribute to the rapid market growth in the region.

 

Transfusion Diagnostics Market Report Coverage

Report Attribute	Details
Forecast Period	2023 – 2032
Market Size Value in 2024	USD 4.5 Billion
Revenue Forecast in 2030	USD 7.1 Billion
Overall Growth Rate	CAGR of 7.5% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Technology, By Application, By End-User, By Geography
By Product Type	Instruments; Reagents & Kits; Software & Services
By Technology	PCR-based Assays; Microarrays; Immunohematology; Next-generation Sequencing (NGS); Other Technologies
By Application	Blood Grouping; Disease Screening; Molecular Typing; Serological Testing
By End-User	Hospitals & Blood Banks; Diagnostic Laboratories; Research & Academic Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of infectious diseases, growing demand for safe blood transfusion procedures, technological advancements in transfusion diagnostics
Pricing and Purchase Options	Customized options available

 

Key Players in the Transfusion Diagnostics Market

• Grifols, S.A.

• Immucor, Inc.

• Hoffmann-La Roche Ltd.

• Bio-Rad Laboratories, Inc.

• Ortho Clinical Diagnostics

• Quotient Suisse SA

• Abbott Laboratories

• DiaSorin S.p.A.

• Siemens Healthineers

• Danaher Corporation

 

Recent Developments

• On November 16, 2023, Grifols introduced the industry's first soluble recombinant protein, Grifols sCD38, designed to block anti-CD38 antibodies in multiple myeloma patients undergoing daratumumab therapy. This innovation ensures accurate blood transfusion tests by preventing drug interference during pre-transfusion compatibility testing.

• On October 6, 2022, Bio-Rad announced the completion of a rollout of its IH-500 immunohematology systems across SANBS's transfusion medicine laboratories. This collaboration aims to enhance the efficiency & accuracy of blood transfusion testing within the SANBS network.

• In November 2023, Immucor, a global leader in transfusion & transplantation diagnostics, was acquired by Werfen. This strategic move is set to expand Werfen's leadership in specialized diagnostics, combining expertise to enhance patient care in transfusion medicine.

 

Future Outlook

The future outlook for the transfusion diagnostics market appears highly promising, driven by the increasing demand for safe & efficient blood transfusion practices worldwide. Advancements in molecular diagnostics, automation & AI-driven blood screening technologies are expected to enhance the accuracy & speed of transfusion compatibility testing. The rising prevalence of chronic diseases, trauma cases & surgical procedures is fueling the demand for reliable blood banking and diagnostic solutions. Additionally, emerging markets in Asia-Pacific & Latin America present significant growth opportunities due to expanding healthcare infrastructure & increased government initiatives to improve blood safety. The adoption of next-generation sequencing (NGS) & nucleic acid testing (NAT) is likely to revolutionize donor screening by reducing transfusion-related infections. However, challenges such as stringent regulatory requirements, high costs of advanced diagnostic solutions, and limited access to blood screening technologies in developing regions may pose hurdles. Despite these challenges, strategic collaborations, R&D investments & the growing focus on automation & digitalization in transfusion medicine are set to drive the market forward, ensuring improved patient outcomes & enhanced transfusion safety globally.